JP2005504725A5 - - Google Patents

Download PDF

Info

Publication number
JP2005504725A5
JP2005504725A5 JP2002577776A JP2002577776A JP2005504725A5 JP 2005504725 A5 JP2005504725 A5 JP 2005504725A5 JP 2002577776 A JP2002577776 A JP 2002577776A JP 2002577776 A JP2002577776 A JP 2002577776A JP 2005504725 A5 JP2005504725 A5 JP 2005504725A5
Authority
JP
Japan
Prior art keywords
methyl
oxo
cyano
dihydro
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002577776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504725A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/009497 external-priority patent/WO2002079149A2/en
Publication of JP2005504725A publication Critical patent/JP2005504725A/ja
Publication of JP2005504725A5 publication Critical patent/JP2005504725A5/ja
Withdrawn legal-status Critical Current

Links

JP2002577776A 2001-03-29 2002-03-26 新規なシアノ置換されたジヒドロピリミジン化合物および疾患を治療する用途 Withdrawn JP2005504725A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29
PCT/US2002/009497 WO2002079149A2 (en) 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Publications (2)

Publication Number Publication Date
JP2005504725A JP2005504725A (ja) 2005-02-17
JP2005504725A5 true JP2005504725A5 (https=) 2005-12-22

Family

ID=23071059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002577776A Withdrawn JP2005504725A (ja) 2001-03-29 2002-03-26 新規なシアノ置換されたジヒドロピリミジン化合物および疾患を治療する用途

Country Status (26)

Country Link
US (1) US6809102B2 (https=)
EP (1) EP1373221A4 (https=)
JP (1) JP2005504725A (https=)
KR (1) KR20030086327A (https=)
CN (1) CN1507435A (https=)
AR (1) AR034585A1 (https=)
BG (1) BG108180A (https=)
BR (1) BR0208405A (https=)
CA (1) CA2442482A1 (https=)
CZ (1) CZ20032645A3 (https=)
EE (1) EE200300474A (https=)
HR (1) HRP20030875A2 (https=)
HU (1) HUP0400350A3 (https=)
IL (1) IL157441A0 (https=)
IS (1) IS6967A (https=)
MX (1) MXPA03008634A (https=)
NO (1) NO20034300L (https=)
PE (1) PE20021013A1 (https=)
PL (1) PL373759A1 (https=)
RU (1) RU2003130961A (https=)
SK (1) SK11062003A3 (https=)
TW (1) TWI228416B (https=)
UY (1) UY27232A1 (https=)
WO (1) WO2002079149A2 (https=)
YU (1) YU75803A (https=)
ZA (2) ZA200306648B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2003051854A1 (fr) * 2001-12-11 2003-06-26 Kyowa Hakko Kogyo Co., Ltd. Dérivé de thiadiazolines
NZ542227A (en) * 2003-03-07 2008-12-24 Astrazeneca Ab Novel fused heterocycles and uses thereof
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
ES2377498T3 (es) * 2003-04-18 2012-03-28 Kyowa Hakko Kirin Co., Ltd. Inhibidor de quinesina en etapa M
CA2528433A1 (en) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005037799A1 (en) * 2003-10-16 2005-04-28 Cytokinetics, Inc. Compounds, compositions, and methods
WO2006008523A1 (en) * 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones usefuel in the treatment and the prevention of cancer
EP1781674A1 (en) * 2004-08-18 2007-05-09 AstraZeneca AB Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
EP1870404A4 (en) * 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd MEANS FOR THE TREATMENT OF A HEMATOPOIETIC TUMOR
JP5060285B2 (ja) * 2005-03-22 2012-10-31 協和発酵キリン株式会社 固形腫瘍治療剤
EP1908755A4 (en) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
MX9703518A (es) 1994-11-16 1997-08-30 Synaptic Pharma Corp Dihidropirimidinas y usos de las mismas.
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
JP2000506904A (ja) 1996-05-16 2000-06-06 シナプティック・ファーマスーティカル・コーポレーション ジヒドロピリミジン類およびその使用
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
WO1998057639A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS
WO1999025345A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
AU768834B2 (en) 1998-04-01 2004-01-08 Yale University A method for selectively modulating the interactions between survivin and tubulin
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
CZ20021428A3 (cs) 1999-10-27 2002-11-13 Cytokinetics, Inc. Způsoby a kompozice vyuľívající chinazoliny
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Similar Documents

Publication Publication Date Title
JP2005504725A5 (https=)
RU2003130961A (ru) Цианозамещенные дигидропиримидиновые соединения и их применение для лечения
RU2326869C2 (ru) Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4), способ их получения, фармацевтическая композиция и способ лечения
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
CA2396824A1 (en) Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
JP2007516173A5 (https=)
JP2011528034A5 (https=)
JP2008509982A5 (https=)
JP2007519754A5 (https=)
AR065814A1 (es) Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados.
JP2005527625A5 (https=)
CA2526866A1 (en) Substituted 3-sulfur indoles for treating a disease mediated by crth2
RU2011109339A (ru) Новые пиррольные ингибиторы s-нитрозоглутатионредуктазы в качестве терапевтических агентов
JP2007519695A5 (https=)
JP4915715B2 (ja) フェニルピリダジン誘導体及びこれを含有する医薬
JP2008520665A5 (https=)
RU2010120682A (ru) Ингибиторы гистондезацетилазы
CA2454703A1 (en) Novel thiophene carboxamide derivatives
JP2012526803A5 (https=)
JP2013506637A5 (https=)
JP2013505949A5 (https=)
JP2009520686A5 (https=)
RU2003115612A (ru) Производные амидоалкилпиперидинов и амидоалкилпиперазинов, пригодные для лечения нарушений нервной системы
JP2009520021A5 (https=)
US6900214B2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases